India, July 27 -- Hengrui Pharma announced that it has entered into a series of strategic agreements with GSK plc (GSK,GSK.L) to jointly develop up to 12 innovative medicines. These programs are expected to significantly advance Hengrui's globalization efforts while creating new growth opportunities for GSK, particularly beyond the year 2031. The selected compounds complement GSK's current pipeline in Respiratory, Immunology & Inflammation (RI&I), and Oncology, and have been evaluated for their potential to be best- or first-in-class treatments. Under the terms of the agreements, GSK will pay $500 million in upfront fees.
One key component of the collaboration is an exclusive worldwide license-excluding mainland China, Hong Kong SAR, Macau...